Symphogen
Gorm Andersen has extensive experience in the pharmaceutical and biotechnology fields, holding significant leadership positions. Gorm Andersen served as Head of Department at Symphogen and LEO Pharma and has also held the role of Department Manager and Head of Department at Novo Nordisk, where responsibilities included managing downstream technologies. Gorm Andersen's academic background includes postdoctoral research at Statens Serum Institut and the Centre for Medical Parasitology at Copenhagen University.
This person is not in the org chart
This person is not in any teams
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.